Addictive behaviours are highly common (prevalence worldwide about 10%), with major impact on the individual and society (contributing to 5% of overall DALYs and mortality) [1 Lancet 2015 ;  386 (9995) : 743-800

Cliccare qui per andare alla sezione Riferimenti, 2 Lancet 2013 ;  382 (9904) : 1575-1586

Cliccare qui per andare alla sezione Riferimenti]. Though a number of evidence-based treatments are available, relapse rates remain high, up to 50% within one year of treatment [3 European Psychiatry 2015 ;  30 (1) :

Cliccare qui per andare alla sezione Riferimenti, 4 Addiction 2015 ;  110 (6) : 920-930

Cliccare qui per andare alla sezione Riferimenti]. Staging of addictive behaviors might contribute to improve this prognosis by indicating which patient could benefit most from which treatment modality.

In DSM-5 clinical staging of addictive disorders is limited to grading the severity of the disorder, based on criterion counts [5 Tijdschr Psychiatr 2014 ;  56 (3) : 206-210

Cliccare qui per andare alla sezione Riferimenti]. However, addictive disorders are highly heterogeneous, with distinct clinical profiles and neurobiological underpinnings of the disorder. Reward-processing deficits are considered a hallmark of addiction. Several additional neurobiological deficits have been identified in addicted individuals, such as dysfunction of brain stress systems, anterior cingulate cortex and habenula.

These neurobiological deficits may identify clinical subgroups of patients with distinct pathophysiology (profiling), or be related to progression of the disorder (staging). This presentation will focus on clinical staging and profiling of addictive behaviors combining neurobiological findings and clinical practice [6 Tijdschr Psychiatr 2012 ;  54 (11) : 941-948

Cliccare qui per andare alla sezione Riferimenti].